PDCD1 and cancer: Checkpoint inhibitors, such as the anti-PD-1 antibody, bind to the checkpoint receptor PD-1 expressed on T cells, stimulating their proliferative capacity and enabling the immune system to reactivate its ability to recognize, attack, and destroy cancer cells.